Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder

Archive ouverte

Amare, Azmeraw, T | Thalamuthu, Anbupalam | Schubert, Klaus, Oliver | Fullerton, Janice, M | Ahmed, Muktar | Hartmann, Simon | Papiol, Sergi | Heilbronner, Urs | Degenhardt, Franziska | Tekola-Ayele, Fasil | Hou, Liping | Hsu, Yi-Hsiang | Shekhtman, Tatyana | Adli, Mazda | Akula, Nirmala | Akiyama, Kazufumi | Ardau, Raffaella | Arias, Bárbara | Aubry, Jean-Michel | Hasler, Roland | Richard-Lepouriel, Hélène | Perroud, Nader | Backlund, Lena | Bhattacharjee, Abesh, Kumar | Bellivier, Frank | Benabarre, Antonio | Bengesser, Susanne | Biernacka, Joanna, M | Birner, Armin | Marie-Claire, Cynthia | Cervantes, Pablo | Chen, Hsi-Chung | Chillotti, Caterina | Cichon, Sven | Cruceanu, Cristiana | Czerski, Piotr, M | Dalkner, Nina | del Zompo, Maria | Depaulo, J, Raymond | Étain, Bruno | Jamain, Stephane | Falkai, Peter | Forstner, Andreas, J | Frisen, Louise | Frye, Mark, A | Gard, Sébastien | Garnham, Julie, S | Goes, Fernando, S | Grigoroiu-Serbanescu, Maria | Fallgatter, Andreas, J | Stegmaier, Sophia | Ethofer, Thomas | Biere, Silvia | Petrova, Kristiyana | Schuster, Ceylan | Adorjan, Kristina | Budde, Monika | Heilbronner, Maria | Kalman, Janos, L | Kohshour, Mojtaba, Oraki | Reich-Erkelenz, Daniela | Schaupp, Sabrina, K | Schulte, Eva, C | Senner, Fanny | Vogl, Thomas | Anghelescu, Ion-George | Arolt, Volker | Dannlowski, Udo | Dietrich, Detlef | Figge, Christian | Jäger, Markus | Lang, Fabian, U | Juckel, Georg | Konrad, Carsten | Reimer, Jens | Schmauß, Max | Schmitt, Andrea | Spitzer, Carsten | von Hagen, Martin | Wiltfang, Jens | Zimmermann, Jörg | Andlauer, Till, F M | Fischer, Andre | Bermpohl, Felix | Ritter, Philipp | Matura, Silke | Gryaznova, Anna | Falkenberg, Irina | Yildiz, Cüneyt | Kircher, Tilo | Schmidt, Julia | Koch, Marius | Gade, Kathrin | Trost, Sarah | Haussleiter, Ida, S | Lambert, Martin | Rohenkohl, Anja, C | Kraft, Vivien | Grof, Paul | Hashimoto, Ryota | Hauser, Joanna | Herms, Stefan | Hoffmann, Per | Jiménez, Esther | Kahn, Jean-Pierre | Kassem, Layla | Kuo, Po-Hsiu | Kato, Tadafumi | Kelsoe, John | Kittel-Schneider, Sarah | Ferensztajn-Rochowiak, Ewa | König, Barbara | Kusumi, Ichiro | Laje, Gonzalo | Landén, Mikael | Lavebratt, Catharina | Leboyer, Marion | Leckband, Susan, G | Tortorella, Alfonso | Manchia, Mirko | Martinsson, Lina | Mccarthy, Michael, J | Mcelroy, Susan | Colom, Francesc | Millischer, Vincent | Mitjans, Marina | Mondimore, Francis, M | Monteleone, Palmiero | Nievergelt, Caroline, M | Nöthen, Markus, M | Novák, Tomas | O’donovan, Claire | Ozaki, Norio | Pfennig, Andrea | Pisanu, Claudia | Potash, James, B | Reif, Andreas | Reininghaus, Eva | Rouleau, Guy, A | Rybakowski, Janusz, K | Schalling, Martin | Schofield, Peter, R | Schweizer, Barbara, W | Severino, Giovanni | Shilling, Paul, D | Shimoda, Katzutaka | Simhandl, Christian | Slaney, Claire, M | Squassina, Alessio | Stamm, Thomas | Stopkova, Pavla | Maj, Mario | Turecki, Gustavo | Vieta, Eduard | Veeh, Julia | Witt, Stephanie, H | Wright, Adam | Zandi, Peter, P | Mitchell, Philip, B | Bauer, Michael | Alda, Martin | Rietschel, Marcella | Mcmahon, Francis, J | Schulze, Thomas, G | Clark, Scott, R | Baune, Bernhard, T

Edité par CCSD ; Nature Publishing Group -

International audience. Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li + PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li + PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi + Gen: N = 2367) and replicated in the combined PsyCourse (N = 89) and BipoLife (N = 102) studies. The associations of Li + PGS and lithium treatment responsedefined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P < 0.05. Li + PGS was positively associated with lithium treatment response in the ConLi + Gen cohort, in both the categorical (P = 9.8 × 10 −12 , R 2 = 1.9%) and continuous (P = 6.4 × 10 −9 , R 2 = 2.6%) outcomes. Compared to bipolar patients in the 1 st decile of the risk distribution, individuals in the 10 th decile had 3.47-fold (95%CI: 2.22-5.47) higher odds of responding favorably to lithium. The results were replicated in the independent cohorts for the categorical treatment outcome (P = 3.9 × 10 −4 , R 2 = 0.9%), but not for the continuous outcome (P = 0.13). Gene-based analyses revealed 36 candidate genes that are enriched in biological pathways controlled by glutamate and acetylcholine. Li + PGS may be useful in the development of pharmacogenomic testing strategies by enabling a classification of bipolar patients according to their response to treatment.

Suggestions

Du même auteur

HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders

Archive ouverte | Le Clerc, Sigrid | CCSD

International audience. Abstract Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD...

Exploring the genetics of lithium response in bipolar disorders

Archive ouverte | Herrera-Rivero, Marisol | CCSD

International audience. Abstract Background Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide ris...

Association of polygenic score for major depression with response to lithium in patients with bipolar disorder

Archive ouverte | Amare, Azmeraw | CCSD

International audience. Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap between ...

Chargement des enrichissements...